
Anthony H Kong

List of Publications by Year in descending order

Source: https://exaly.com/author-pdf/4305784/publications.pdf Version: 2024-02-01



#	Article	IF	CITATIONS
1	Local radiotherapy and E7 RNA-LPX vaccination show enhanced therapeutic efficacy in preclinical models of HPV16+ cancer. Cancer Immunology, Immunotherapy, 2022, 71, 1975-1988.	4.2	11
2	Safety and Treatment Outcomes of Nivolumab for the Treatment of Recurrent or Metastatic Head and Neck Squamous Cell Carcinoma: Retrospective Multicenter Cohort Study. Cancers, 2021, 13, 1413.	3.7	13
3	WEE1 Inhibitor: Clinical Development. Current Oncology Reports, 2021, 23, 107.	4.0	38
4	Comprehensive Genomic and Transcriptomic Analysis of Three Synchronous Primary Tumours and a Recurrence from a Head and Neck Cancer Patient. International Journal of Molecular Sciences, 2021, 22, 7583.	4.1	3
5	TNM 8 staging is a better prognosticator than TNM 7 for patients with locally advanced oral cavity squamous cell carcinoma treated with surgery and post-operative radiotherapy. Radiotherapy and Oncology, 2021, 160, 54-60.	0.6	2
6	Centralised RECIST Assessment and Clinical Outcomes with Lenvatinib Monotherapy in Recurrent and Metastatic Adenoid Cystic Carcinoma. Cancers, 2021, 13, 4336.	3.7	9
7	A phase II study of monalizumab in patients with recurrent/metastatic squamous cell carcinoma of the head and neck: The I1 cohort of the EORTC-HNCG-1559 UPSTREAM trial. European Journal of Cancer, 2021, 158, 17-26.	2.8	33
8	Concurrent cisplatin or cetuximab with radiotherapy for HPV-positive oropharyngeal cancer: Medical resource use, costs, and quality-adjusted survival from the De-ESCALaTE HPV trial. European Journal of Cancer, 2020, 124, 178-185.	2.8	11
9	Phase I trial of WEE1 inhibition with chemotherapy and radiotherapy as adjuvant treatment, and a window of opportunity trial with cisplatin in patients with head and neck cancer: the WISTERIA trial protocol. BMJ Open, 2020, 10, e033009.	1.9	23
10	Radiotherapy plus cisplatin or cetuximab in low-risk human papillomavirus-positive oropharyngeal cancer (De-ESCALaTE HPV): an open-label randomised controlled phase 3 trial. Lancet, The, 2019, 393, 51-60.	13.7	697
11	Evidence for the approach to the diagnostic evaluation of squamous cell carcinoma occult primary tumors of the head and neck. Oral Oncology, 2019, 88, 145-152.	1.5	40
12	Personalized biomarker-based treatment strategy for patients with squamous cell carcinoma of the head and neck: EORTC position and approach. Annals of Oncology, 2018, 29, 2313-2327.	1.2	47
13	The clinical impact of using complex molecular profiling strategies in routine oncology practice. Oncotarget, 2018, 9, 20282-20293.	1.8	15